skip to content
  1. Home
  2. >
  3. Questions
  4. >
  5. RX: On May 23 I asked for 5iR thoughts on RX recent quarter. [BioSyent Inc.]
You can view 2 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: On May 23 I asked for 5iR thoughts on RX recent quarter. I see that RX does not report until May 26. So would you please hold off my request until they report. Thanks ... Cal
Asked by cal on May 29, 2023
5i Research Answer:

EPS was 10c vs 13c last year (we do not have estimates, there is only one analyst). Revenue fell 8% to $6.4M. EBITDA fell 23% to $1.5M. RX bought back 52,800 shares in the Q1. International sales were very weak this quarter. Still, RX does expect higher growth for the full year. The balance sheet remains strong with $25M net cash. Insiders own ~14%. Not the best quarter. At 18X earnings we would consider it 'OK' but not compelling.